Advertisement
Advertisement
September 21, 2015
CIRSE Begins CIREL Registry of Terumo's LifePearl Microspheres for Transcatheter Chemoembolization
September 22, 2015—The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) announced that the CIRSE Registry for LifePearl Microspheres (CIREL) will prospectively observe the administration of irinotecan‐eluting microspheres, a newly CE Mark–approved transcatheter chemoembolization (TACE) system. The European-wide observational trial will begin in early 2016. In April, Terumo announced European CE Mark approval for the LifePearl drug-elutable microsphere.
According to CIRSE, the primary endpoint of CIREL is to map the exact indications that the device is being used for and at which stage in treatment it is being applied. CIREL is the second major observational study led solely by CIRSE, noted the society.
In the press release, Prof. Philippe Pereira, MD, commented, “This observational study will not only provide us with robust, multicenter data on the precise use and efficacy and safety profiles of this particular device, but also give some insight into how TACE can fit into the established lines of standard clinical practice in Europe.”
Advertisement
Advertisement
